MSLN and cancer: Our previous preclinical studies of anti‐mesothelin hYP218 CAR T cells targeting the membrane‐proximal epitope of mesothelin have shown promising results, including effective tumour cell eradication and increased survival in animal models involving various cancer types, such as mesothelioma, pancreatic, and ovarian cancers.28